We Advance Science
Our mission is to develop lifesaving accessible immunotherapies for the most prevalent diseases plaguing humanity
Tevogen has evolved into next-gen biotech with core organizational capabilities, robust IP portfolio, promising research pipeline, completed lead T cell product POC trial, and received global recognition for its patient centric, purpose driven business model – all in less than two years since its formation.
We invite you to learn more and share your thoughts.
Latest News
Tevogen Bio – December 7th, 2022
Tevogen Bio – December 1st, 2022
Tevogen Bio – November 22nd, 2022
Tevogen Bio – October 27th, 2022
About Us
Tevogen Bio is driven by a team of distinguished scientists and experienced biopharmaceutical leaders who have developed and commercialized multiple franchises. In collaboration with key strategic partners, the company moved its lead product from discovery to clinical phase within 18 months of inception, shaving years off the industry’s standard for drug development timelines.
Tevogen leadership believes that accessible personalized immunotherapies are the next frontier of medicine and disruptive business models are required to sustain medical innovation in the post-pandemic world. The company’s proprietary technology overcomes traditional barriers to the broad application of targeted T cell therapies through advances in speed to patient and product purity. Tevogen’s focus on organizational and manufacturing efficiency is core to its successful biopharma business model and the company’s goal is to make personalized immunotherapies accessible to the masses for the first time. Tevogen Bio’s research pipeline includes targeted CD8+ T Lymphocyte therapeutics for the treatment of common cancers and difficult to eradicate serious viral infections.
Our Innovative Science
Tevogen’s patented allogeneic T cell technology is a major scientific breakthrough
Target Tuning Platform to overcome potential immune escape of SARS-CoV-2 viral variants.
Target Specific T Cell Receptor Engineered CD8+CTL (TCR-Ts) for treatment of Cancers and Viral Infections.
Technology to Bring Targets for Tevogen’s Allogeneic CD8+Cytotoxic T Lymphocytes to Cancer Cells being Marked for Elimination.
Learn more about our Precision T Cells and their use in virology, oncology, and neurology
Pipeline
We are committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need
COVID-19 and Tevogen’s investigational therapy
Investor Relations
Purpose, innovations, and opportunity to join before Tevogen’s next growth spurt
Message From the CEO
Tevogen was created based on the audacious goal of finding a cure for cancer. This dream inspired us to pursue the development of life-saving therapies for some of the most prevalent illnesses plaguing humanity today.
Our success is rooted in passion and perseverance, and is backed by rigorous science. However, our unrelenting optimism – and belief that learning and adapting means improving – is what propelled us to this moment.
Our corporate culture encourages people to contribute their unique and diverse perspectives, to harness their optimism and creativity, and to be ready to learn and develop solutions together towards a common and greater purpose. We all are different and think differently, it’s okay to fail and make mistakes but learn from the failures – that mindset, respect for each other and irrational optimism is what has made Tevogen a reality.
I am confident in Tevogen’s success, and in our investigational therapies. We have brought together accomplished experts in immunotherapy and biopharma business to contribute their knowledge in a practical and efficient way. Tevogen is uniquely positioned to combat several large-scale health problems of today, including COVID-19. I am equally confident in our rapidly advancing and diverse research portfolio in virology, oncology, and neurology.
One of our objectives is to ensure that all people, regardless of socioeconomic status, are able to afford our therapies. Tevogen’s aim is to be the first biotech to offer personalized T cell therapeutics at commercially attractive and economically viable price. As the founder of Tevogen and its CEO, I am personally delighted to see that what started as an intrepid goal may very well play a critical role in overcoming the biggest public health crisis of our time.
Ryan Saadi, MD, MPH
CEO, Tevogen Bio
© 2021 Tevogen Bio. All Rights Reserved.